Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis

Table 2 Summary of patient characteristics

Patient characteristics	Number of studies (n = 299)^{a, b}	Percentage of studies
Number of patients	58,412
Mean (median sample size)	197 (105)^c
Mean % female	53.1^d
Age category
Adults and elderly (aged ≥18 years)	192	64.21
Adults only (aged ≥18 to ≤65 years)	56	18.73
Children only (aged <18 years)	25	8.36
All ages	10	3.34
Children and adults (aged ≤65 years)	8	2.68
Not reported	8	2.68
Cancer type^e
Lung and respiratory	144	48.16
Breast	110	36.79
Gynecological	98	32.78
Hematological	91	30.43
Unspecified or unknown	87	29.10
Head and neck	87	29.10
Gastrointestinal	86	28.76
Genitourinary	81	27.09
Sarcoma	47	15.72
Not reported	43	14.38
Nervous system	13	4.35
Skin	11	3.68
Optic	5	1.67
Germ cell	5	1.67
Other	3	1.00
Adenocarcinoma	2	0.67
Musculoskeletal	1	0.33
Chemotherapy details
Cisplatin administered^f	177	59.20
Cisplatin dose ≥ 50 mg/m²	116	38.80
Concomitant radiotherapy	12	4.01
Adjuvant	14	4.68
Neoadjuvant	4	1.34
Patient background details
History of motion sickness	19	6.35
History of CINV	29	9.70

CINV chemotherapy induced nausea and vomiting
^aIncludes unpublished data from conference abstracts and trial protocols (Adel et al. 2006, Tabei et al. 2006, Trifilio et al. 2006, Carrec et al. 2007, Kadota et al. 2007, Piyush 2011)
^bExcept where indicated otherwise
^cOne study did not report sample size (n = 1)
^dEighteen studies did not report female population size (n = 18)
^eThe majority of studies included patients with different diagnoses
^fIncludes the 116 studies with a cisplatin dose ≥ 50 mg/m²

ISSN: 1741-7015